Nous aimerions que vous fassiez partie de notre communauté. Rejoignez notre Discord pour échanger avec nous et les autres membres !

Ticker
SKIKON.CO

Price
825.90
Stock movement down
-9.50 (-1.09%)
Company name
SKAGEN Kon-Tiki A
Exchange
(CO
,
Currency
DKK
)
Capitalisation boursière
-
Valeur d'entreprise
-
Cours/chiffre d'affaires
-
Cours/valeur comptable
-
Rendement du div
-
Croissance du div
-
Années de croissance
-
Versement FCF
-
Trailing P/E
-
P/E prévisionnel
-
PEG
-
Croissance EPS
-
Rendement sur 1 an
19.58%
Rendement sur 3 ans
-1.52%
Rendement sur 5 ans
9.62%
Rendement sur 10 ans
3.84%
Dernière modification : 2025-09-05

DIVIDENDES

SKIKON.CO ne verse pas de dividendes

VALORISATION

Ratios de valorisation

Loading...
Données de ratios de valorisation
Trailing P/E-
Cours/OCF-
Cours/FCF-
Cours/EBITDA-
EV/EBITDA-

Valorisation (Chiffre d'affaires/valeur comptable)

Loading...
Données de valorisation (Chiffre d'affaires/valeur comptable)
Cours/chiffre d'affaires-
Cours/valeur comptable-
EV/chiffre d'affaires-

DONNEES FINANCIERES

INFORMATIONS SUR LES ACTIONS

Graphique boursier

Loading...
Données du prix des actions
Ouverture862.50
Max journalier862.50
Min journalier862.50
Volume journalier0K
Niveau record1070.92
Estimation des analystes sur 1 an-
Beta-
EPS (TTM)-
Dividende par action-
Date ex-div-
Prochaine date de bénéfices-

Potentiel de baisse

Loading...
Données du potentiel de baisse
SKIKON.COS&P500
Baisse de prix actuelle par rapport au niveau record-19.46%-1.06%
Baisse de prix actuelle la plus importante-57.82%-56.47%
Date de la baisse la plus importante27 Oct 20089 Mar 2009
Baisse moyenne par rapport au record-14.05%-10.99%
Délai moyen pour nouveau record26 days12 days
Délai max pour nouveau record654 days1805 days
INFORMATIONS SUR LA SOCIETE
SKIKON.CO (SKAGEN Kon-Tiki A) company logo
Capitalisation boursière
-
Catégorie de capitalisation boursière
Small-cap
Description
SKAGEN - Kon-Tiki fund is an open-ended equity mutual fund launched and managed by Skagen AS. The fund invests in public equity markets of emerging countries across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund invests in stocks of companies across diversified market capitalizations. It invests in value stocks of companies. It benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. SKAGEN - Kon-Tiki fund was formed on April 5, 2002 and is domiciled in Norway.
Employés
0
Communication financière
-
CEO
Pays
Denmark
Ville
Type d'action
-
Statut CCC
-
Fréquences des dividendes
-
EVENEMENTS ET PRESENTATIONS
EvénementsPrésentations
Loading...
COMPRENDRE LE METIER
Loading...
ACTUALITES DE LA SOCIETE
Toute l'actualitéCommuniqués de presse
Lysaker, 28 October 2025 The suspension is lifted for the below funds, and the live trading on Nasdaq Copenhagen can resume. Regards Storebrand Asset Management AS Contacts: Henrik Budde Gantzel, Dire...
28 octobre 2025
Lysaker, 28 October 2025 The below funds are suspended from the live trading on Nasdaq Copenhagen due to technical issues which affect NAV calculations, and hence, challenges to provide intrinsic valu...
28 octobre 2025
Lysaker, 27 October 2025 This is a re-submission of the announcement posted at 14:46, with reference to the correct fund (SKAGEN Focus A) at the bottom of this text. With reference to Nasdaq Copenhage...
27 octobre 2025
Lysaker, 27 October 2025 With reference to Nasdaq Copenhagen's rules for issuers of UCITS units, we hereby notify that incorrect intrinsic values were reported on 24 October for SKAGEN Focus A as deta...
27 octobre 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
9 septembre 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
9 septembre 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
9 septembre 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
9 septembre 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
9 septembre 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
9 septembre 2025
Page suivante